IP Library Granted Patent US 9,353,188
Granted Patent B2
US 9,353,188 · App. 14/008,085 · Granted May 31, 2016

Modulators of Plexin B2 activity

Inventors: Guofu Hu (Wellesley, MA); Wenhao Yu (Newton, MA)
Assignees: President and Fellows of Harvard College; Tufts Medical Center, Inc.
C07K16/40C07K14/71C07K14/715C07K16/28C07K16/30G01N33/6863A61K2039/505C07K2317/34C07K2317/73C07K2317/76C12N15/1138C12N2310/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,353,188
App. No.
14/008,085
Granted
May 31, 2016
Kind
B2
Abstract

Disclosed herein are novel compositions and methods for the inhibition of Plexin B2-mediated Angiogenin activity. Such compositions and methods are useful, for example, for the treatment of cancer, the treatment of wet AMD and the inhibition of angiogenesis. Also disclosed herein are methods of determining whether a test agent is a modulator of Plexin B2 activity.

Claims (2)

1. An isolated antibody or antigen binding fragment thereof that specifically binds to an Angiogenin (ANG) binding epitope of Plexin B2, wherein the ANG binding epitope consisting of an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

2. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof inhibits the binding of Angiogenin to Plexin B2.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 23, 2014
From: TUFTS MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032115/0677 →
Continuity (3)
Provisional Application 61468271 · Mar 28, 2011
Provisional Application 61543992 · Oct 6, 2011
Related Publication 20140105903A1 · Apr 17, 2014